Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Advertising and Sponsorship
    • Profile & Readership
    • Contact Us
    • Latest News
    • Privacy & Cookies Policies
    • Terms of Use
    • Advertising Terms
    • Issue 81
    • Issue 80
    • Issue 79
    • Issue 78
    • Issue 77
    • Issue 76
    • Issue 75
    • Issue 74
    • Issue 73
    • Issue 72
    • Issue 71
    • Issue 70
    • View All
    • About the Awards
    • Awards Timetable
    • Awards Winners
    • Submit Nominations
    • Testimonials
    • Media Room
    • FAQ
    • Asset Management Awards
    • Brand of the Year Awards
    • Business Awards
    • Cash Management Banking Awards
    • Banking Technology Awards
    • CEO Awards
    • Customer Service Awards
    • CSR Awards
    • Deal of the Year Awards
    • Corporate Governance Awards
    • Corporate Banking Awards
    • Digital Transformation Awards
    • Fintech Awards
    • Education & Training Awards
    • ESG & Sustainability Awards
    • ESG Awards
    • Forex Banking Awards
    • Innovation Awards
    • Insurance & Takaful Awards
    • Investment Banking Awards
    • Investor Relations Awards
    • Leadership Awards
    • Islamic Banking Awards
    • Real Estate Awards
    • Project Finance Awards
    • Process & Product Awards
    • Telecommunication Awards
    • HR & Recruitment Awards
    • Trade Finance Awards
    • The Next 100 Global Awards
    • Wealth Management Awards
    • Travel Awards
    • Years of Excellence Awards
    • Publishing Principles
    • Ownership & Funding
    • Corrections Policy
    • Editorial Code of Ethics
    • Diversity & Inclusion Policy
    • Fact Checking Policy
    Original content: Global Banking and Finance Review - https://www.globalbankingandfinance.com

    A global financial intelligence and recognition platform delivering authoritative insights, data-driven analysis, and institutional benchmarking across Banking, Capital Markets, Investment, Technology, and Financial Infrastructure.

    Copyright © 2010-2026 - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    1. Home
    2. >Headlines
    3. >Novo Nordisk cuts hit production line jobs at key US plant, posts show
    Headlines

    Novo Nordisk Cuts Hit Production Line Jobs at Key US Plant, Posts Show

    Published by Global Banking & Finance Review®

    Posted on October 7, 2025

    3 min read

    Last updated: January 21, 2026

    Add as preferred source on Google
    Novo Nordisk cuts hit production line jobs at key US plant, posts show - Headlines news and analysis from Global Banking & Finance Review
    Tags:job creationunemployment ratesfinancial crisis

    Quick Summary

    Novo Nordisk is reducing its workforce at a major US plant as part of a global restructuring to cut costs and enhance competitiveness.

    Novo Nordisk Reduces Workforce at Major U.S. Manufacturing Facility

    (In paragraph 8, removes reference to the layoff of a strategic communications manager)

    By Maggie Fick and Soren Jeppesen

    LONDON/COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk has laid off dozens of employees at the largest U.S. manufacturing site for its blockbuster obesity and diabetes drugs, a Reuters review of LinkedIn posts showed, a signal of where it is making cuts in a major restructuring under new CEO Mike Doustdar.

    The previously unreported cuts included staff in manufacturing roles, from quality control to production line technicians, at Novo's major Clayton, North Carolina, plant and other facilities in the state, an analysis of 73 posts and profiles show.

    The layoffs, while only a small part of a planned 9,000 job cuts globally, underscore how Novo is cutting back even on frontline production in the top market for Wegovy as it looks to sharpen its focus, trim costs, and claw back lost ground in fierce competition with rival Eli Lilly.

    The cuts, which follow earlier ones focused on the obesity education team in the U.S., come as the administration of President Donald Trump pressures pharmaceutical companies to expand U.S. drug production and create more domestic jobs.

    The Danish drugmaker last year became Europe's most valuable listed company on unprecedented demand for weight-loss drugs before a sharp share price slide as sales growth slowed. It is now trying to turn around its fortunes and reduce costs and staff that bloated as it rode the Wegovy boom.

    A Novo spokesperson declined a Reuters request for further details beyond last month's global layoffs announcement. "This process takes time and our highest priority is to support our employees," the spokesperson said.

    PLANT MAKES WEGOVY, OZEMPIC

    The announced wider cuts helped boost Novo's shares, though the company has provided little detail about its plans. It said around 5,000 jobs would be cut in its native Denmark.

    The North Carolina cuts hit technical manufacturing workers, project coordinators, and an HR assistant, the posts revealed. Of the total, 47 directly posted they were looking for work or had been laid off.

    Novo's Clayton facility makes semaglutide, the active ingredient in Wegovy and diabetes drug Ozempic. It also does manufacturing steps including filling, finishing and packaging the injections. It also will play a key role in producing the new pill version of Wegovy once that becomes available.

    CEO Doustdar this month heralded an ongoing $4.1 billion expansion at the North Carolina plant that employed some 2,500 people in 2024 and was expected to add 1,000 more.

    Reuters could not determine the exact number or the reason for the layoffs in Clayton, which came three weeks after Doustdar announced the broader restructuring.

    Reuters contacted about 30 of the Novo employees who posted on LinkedIn that they had been laid off. One replied, saying a non-disclosure agreement prevented them from speaking to the media.

    (Reporting by Maggie Fick in London and Soren Jeppesen in Copenhagen; Editing by Adam Jourdan and Bill Berkrot)

    Key Takeaways

    • •Novo Nordisk is cutting jobs at its largest US manufacturing site.
    • •The layoffs are part of a global restructuring plan under new CEO.
    • •The Clayton, NC plant produces key drugs like Wegovy and Ozempic.
    • •The restructuring aims to reduce costs and improve competitiveness.
    • •The company is expanding the Clayton facility despite layoffs.

    Frequently Asked Questions about Novo Nordisk cuts hit production line jobs at key US plant, posts show

    1What is a layoff?

    A layoff is a termination of employment by an employer, often due to economic conditions or company restructuring, where employees are let go temporarily or permanently.

    2What is a manufacturing role?

    A manufacturing role involves tasks related to the production of goods, including operating machinery, quality control, and assembly line work.

    3What is a CEO?

    A CEO, or Chief Executive Officer, is the highest-ranking executive in a company, responsible for making major corporate decisions and managing overall operations.

    4What is company restructuring?

    Company restructuring is a process of reorganizing a company's structure, operations, or finances to improve efficiency, adapt to market changes, or reduce costs.

    5What are job cuts?

    Job cuts refer to the reduction of staff within a company, often as a result of downsizing, financial difficulties, or strategic changes.

    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    More from Headlines

    Explore more articles in the Headlines category

    Image for North Korea's Kim Jong Un welcomed Belarus President Lukashenko to Pyongyang, KCNA says
    North Korea's Kim Jong Un Welcomed Belarus President Lukashenko to Pyongyang, Kcna Says
    Image for Ukrainian drones kill two in Russian border region of Belgorod, governor says
    Ukrainian Drones Kill Two in Russian Border Region of Belgorod, Governor Says
    Image for Iran wants Lebanon included in any ceasefire, sources say
    Iran Wants Lebanon Included in Any Ceasefire, Sources Say
    Image for Vance due to visit Hungary on April 7-8 ahead of key election, say sources
    Vance Due to Visit Hungary on April 7-8 Ahead of Key Election, Say Sources
    Image for Belgian police break up migrant smuggling network, four people arrested
    Belgian Police Break up Migrant Smuggling Network, Four People Arrested
    Image for Russia sought to blackmail US using intelligence to Iran, Zelenskiy says
    Russia Sought to Blackmail US Using Intelligence to Iran, Zelenskiy Says
    Image for Italy's tourism minister resigns, ending standoff with PM Meloni
    Italy's Tourism Minister Resigns, Ending Standoff With PM Meloni
    Image for In Lebanon, paramedics mourn their own killed in Israeli strike
    In Lebanon, Paramedics Mourn Their Own Killed in Israeli Strike
    Image for Italy tourism minister resigns, obeying PM Meloni
    Italy Tourism Minister Resigns, Obeying PM Meloni
    Image for Swiss prosecutors not involved with Paris probe at bank Edmond de Rothschild
    Swiss Prosecutors Not Involved With Paris Probe at Bank Edmond De Rothschild
    Image for Lost remains of French musketeer d'Artagnan may have been found in Dutch church
    Lost Remains of French Musketeer d'Artagnan May Have Been Found in Dutch Church
    Image for Doctors in England plan six-day strike after government pay offer rejected
    Doctors in England Plan Six-Day Strike After Government Pay Offer Rejected
    View All Headlines Posts
    Previous Headlines PostCrew Member of Attacked Dutch Cargo Ship Dies of Injuries, Says Vessel's Operator
    Next Headlines PostEU States Edge Towards Deal to Curb Russian Diplomat Movements